WO2000074750A2 - Dispositif et procede de distribution de fluide a injection directe - Google Patents

Dispositif et procede de distribution de fluide a injection directe Download PDF

Info

Publication number
WO2000074750A2
WO2000074750A2 PCT/US2000/040118 US0040118W WO0074750A2 WO 2000074750 A2 WO2000074750 A2 WO 2000074750A2 US 0040118 W US0040118 W US 0040118W WO 0074750 A2 WO0074750 A2 WO 0074750A2
Authority
WO
WIPO (PCT)
Prior art keywords
vessel
fluid delivery
fluid
catheter
cannula
Prior art date
Application number
PCT/US2000/040118
Other languages
English (en)
Inventor
Inc. Corvascular
Original Assignee
Morales, Stephen
Hogendijk, Michael
Knopp, Peter
Iki, Kobi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morales, Stephen, Hogendijk, Michael, Knopp, Peter, Iki, Kobi filed Critical Morales, Stephen
Priority to AU64023/00A priority Critical patent/AU6402300A/en
Publication of WO2000074750A2 publication Critical patent/WO2000074750A2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/01—Introducing, guiding, advancing, emplacing or holding catheters
    • A61M25/06—Body-piercing guide needles or the like
    • A61M25/0606—"Over-the-needle" catheter assemblies, e.g. I.V. catheters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/02—Surgical instruments, devices or methods, e.g. tourniquets for holding wounds open; Tractors
    • A61B2017/0237—Surgical instruments, devices or methods, e.g. tourniquets for holding wounds open; Tractors for heart surgery
    • A61B2017/0243—Surgical instruments, devices or methods, e.g. tourniquets for holding wounds open; Tractors for heart surgery for immobilizing local areas of the heart, e.g. while it beats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/12—Blood circulatory system
    • A61M2210/125—Heart
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/01—Introducing, guiding, advancing, emplacing or holding catheters
    • A61M25/06—Body-piercing guide needles or the like
    • A61M25/065—Guide needles

Definitions

  • the present invention relates generally to medical and surgical devices, and in particular to fluid delivery apparatus and methods for the local, direct delivery of a fluid or drug, such as a cardioplegia agent, into a vessel within a patient's vasculature system, such as a coronary vessel on a beating heart.
  • a fluid or drug such as a cardioplegia agent
  • the conventional practice in performing coronary artery bypass graft procedures on the heart of a patient is to open the chest by making a longitudinal incision along the sternum (e.g., a partial or median sternotomy), placing the patient on a cardiopulmonary bypass (CPB) (heart-lung) machine, stopping the heart from beating by administering a conventional cardioplegia solution (e.g., a potassium chloride solution) to the heart, and then attaching the coronary artery bypass graft(s) to the coronary arteries (and/or aorta in the case of the proximal end of a free graft vessel).
  • a conventional cardioplegia solution e.g., a potassium chloride solution
  • the heart-lung machine is needed to maintain the blood circulation through the patient and to provide gas and heat exchange surfaces.
  • conventional open-chest procedures many of which are related to the use of a heart-lung machine.
  • the use of a heart- lung machine has been shown to be the cause of many of the complications that have been reported in conventional coronary artery bypass graft procedures, such as complement and neutrophil activation, adverse neuropsychologic effects, coagulopathy, and even stroke.
  • the period of CPB should be minimized, if not avoided altogether, to reduce patient morbidity.
  • Minimally invasive techniques i.e., surgical techniques that avoid the partial or median sternotomy and/or the use of CPB
  • CPB cardiac surgery techniques
  • One approach to minimally invasive cardiac surgery is an endoscopic procedure in which access to the heart is gained through several small openings, or ports, in the chest wall of a patient.
  • the endoscopic method allows surgeons to stop the heart without cracking the chest by utilizing a series of internal catheters to stop blood flow through the aorta and to administer a conventional cardioplegia solution (e.g., a potassium chloride solution) to facilitate stopping the heart.
  • a conventional cardioplegia solution e.g., a potassium chloride solution
  • the cardioplegia solution paralyzes the electrical activity of the heart and renders the heart substantially totally motionless during the surgery.
  • the endoscopic approach utilizes groin cannulation to establish cardiopulmonary bypass (CPB) which takes over the function of the heart and lungs by circulating oxygenated blood throughout the body.
  • CPB cardiopulmonary bypass
  • an intraaortic balloon catheter that functions as an internal aortic clamp by means of an expandable balloon at its distal end is used to occlude blood flow in the ascending aorta from within.
  • a full description of an example of one preferred endoscopic technique is found in United States Patent No. 5,752,733, the complete disclosure of which is incorporated by reference herein.
  • a primary drawback of endoscopic cardiac surgery procedures is that such procedures do not avoid the damaging effects of CPB.
  • CPB has been shown to be the cause of many of the complications that have been reported in conventional coronary artery bypass graft procedures, such as stroke. The period of cardiopulmonary bypass should be minimized, if not avoided altogether, to reduce patient morbidity.
  • MIDCAB minimally invasive direct coronary artery bypass grafting
  • the heart typically is accessed through a mini-thoracotomy (i.e., a 6 to 8 cm incision in the patient's chest) which also avoids the sternal splitting incision of conventional cardiac surgery.
  • the heart may also be accessed through a partial or median sternotomy in an off-pump coronary artery bypass graft (OPCAB) technique which gives the surgeon greater direct access to the heart.
  • OPCAB off-pump coronary artery bypass graft
  • the anastomosis procedure is then performed under direct vision on the beating heart without the use of CPB or potassium chloride cardioplegia.
  • TransarrestTM platform a new minimally invasive surgical platform known as the TransarrestTM platform has been developed to minimize the cardiac motion of the beating heart while avoiding the need for CPB, aortic cross-clamping and conventional cardioplegia.
  • the TransarrestTM platform employs a novel pharmaceutical approach to stabilizing the heart.
  • compositions, devices, and methods which are useful for medical and surgical procedures which require precise control of cardiac contraction, such as minimally invasive CABG procedures.
  • the TransarrestTM platform involves the administration of a novel cardioplegia solution which provides for precise heart rate and rhythm control management while maintaining the ability of the heart to be electrically paced (i.e., which does not paralyze the electrical activity of the heart as with conventional cardioplegia solutions).
  • the novel cardioplegia solution comprises a pharmaceutical composition which is capable of inducing reversible ventricular asystole in the heart of a patient, while maintaining the ability of the heart to be electrically paced.
  • "Reversible ventricular asystole” refers to a state wherein autonomous electrical conduction and escape rhythms in the ventricle are suppressed.
  • a state of the heart may be induced wherein the heart is temporarily slowed to at least about 25 beats per minute or less, and often about 12 beats per minute or less.
  • the induced ventricular asystole is reversible and after reversal, the heart functions are restored, and the heart is capable of continuing autonomous function.
  • the pharmaceutical composition may preferably include, for example, an atrioventricular (“AV”) node blocker and a beta blocker.
  • AV node blocker refers to a compound capable of reversibly suppressing autonomous electrical conduction at the AV node, while still allowing the heart to be electrically paced to maintain cardiac output.
  • the AV node blocker, or the composition comprising the AV node blocker reduces or blocks ventricular escape beats and cardiac impulse transmission at the AV node of the heart, while the effect on depolarization of the pacemaker cells of the heart is minimal or nonexistent.
  • the beta blocker is provided in one embodiment in an amount sufficient to substantially reduce the amount of AV node blocker required to induce ventricular asystole.
  • the AV node blocker may be present in the composition in an amount which is 50% or less by weight, or optionally about 1 to 20% by weight of the amount of AV node blocker alone required to induce ventricular asystole.
  • the pharmaceutical composition such as an AV node blocker, capable of causing ventricular asystole in a preferred embodiment is a cholingeric agent such as carbachol, although other cholingeric agents may be used as well such as acetylcholine, methacholine, bethanechol, arecoline, norarecoline, neostigmine, pyridostigmine, and other agents that increase cyclic GMP levels by direct or indirect cholinergic receptor stimulation.
  • a cholingeric agent such as carbachol
  • other cholingeric agents may be used as well such as acetylcholine, methacholine, bethanechol, arecoline, norarecoline, neostigmine, pyridostigmine, and other agents that increase cyclic GMP levels by direct or indirect cholinergic receptor stimulation.
  • exemplary AV node blockers include calcium channel blockers, adenosine Al receptor agonists, adenosine deaminase inhibitors, cholinesterase inhibitors, monamine oxidase inhibitors, serotoninergic agonists, antiarrythmics, cardiac glycosides, and local anesthetics.
  • AV node blockers examples include verapamil, diltiazem, lidocaine, procaine, procainamide, quinidine, choloroquine, amiodarone, pilocarpine, ethmozine, propafenone, flecainide, encainide, tranylcypromine, serotonin, adenosine, digoxin, digitalis, dipyridamole, ibutilide, zapranest, sotalol, metoclopromide and combinations thereof.
  • the beta blocker is propranolol, although other suitable beta blockers may be used as well.
  • beta blockers include atenolol, acebutolol, labetalol, metoprolol, nadolol, oxprenolol, penbutolol, pindolol, sotalol and timolol, and any combinations or pharmaceutically acceptable salts thereof.
  • celiprolol, betaxolol, bevantolol, bisoprolol, esmolol, alprenolol, carterolol, or teratolol may be used.
  • the beta blocker may be any naturally occurring or synthetic analogue capable of blocking beta-adrenergic receptor sites.
  • the administration of the beta blocker is preferably prior to, or contemporaneously with, the administration of the cholinergic agent, and results in a synergistic effect between the beta blocker and the cholinergic agent.
  • a cholinergic agent such as carbachol
  • a beta-blocker such as propranolol
  • the beta- blocker propranolol and the AV node blocker carbachol are serially administered in an initial intracoronary bolus to induce reversible ventricular asystole of the heart, and then carbachol is administered as a periodic or continuous intracoronary infusion to maintain ventricular asystole during the course of the surgical procedure.
  • an intracoronary injection of about 0.5 to 4 mg, for example about 1 mg, of propranolol is administered by intracoronary infusion over a time period of about 0.5 to 3.0 minutes, e.g., about 1 minute, preferably followed by a saline flush, such as 2 mL saline flush.
  • a saline flush such as 2 mL saline flush.
  • an intracoronary bolus injection of about 0.01 to 0.5 mg, e.g., about 0.025 to 0.3 mg, e.g., about 0J mg carbachol administered over about 0.5 to 3.0 minutes, e.g., about 1 minute, to initially induce ventricular asystole.
  • carbachol is administered as one or more periodic bolus infusions (e.g., about 0.05 mg/bolus) or as an intracoronary infusion at a rate of about 0.01 to 0.3 mg/min, e.g., about 0.025 to 0.3 mg/min, for example, about 0.01 to 0J mg/min, e.g., about 0.05 to 0J mg/min, e.g., about 0.0825 mg/min, for a time period of about 5 to 90 minutes, preferably about 30 to 90 minutes, depending on the length of the procedure.
  • a dosage amount of about 1.0 mg of phenylephrine or lavofed may be administered to control the hypotensive effects associated with carbachol administration. In most situations, atropine (about 1 mg) is used to reverse ventricular asystole and restore the heart to its normal function.
  • Electrical pacing wires are connected to the right ventricle and/or left ventricle and/or atria and are used to pace the heart using a novel foot-actuated pacer control system to maintain the patient's blood circulation during the periods in which the surgeon is temporarily not performing the surgical procedure.
  • the surgeon can control the pacing of the heart with a convenient foot pedal and can controllably stop the heart as sutures are placed in the vessel walls.
  • the pharmaceutical compositions, devices and methods for drug delivery, and systems for pacing the heart give a surgeon complete control of the beating heart.
  • the TransarrestTM procedure described above can be used to facilitate any surgical procedure within the thoracic cavity or other body cavity which requires intermittent stoppage of the heart, reduced oxygen consumption or elimination of movements caused by pulsatile blood flow, whether access is gained to the body cavity via a partial or median sternotomy incision, via a mini-thoracotomy incision, or via one or more small incisions or ports in the chest wall.
  • the pharmaceutical composition is delivered locally to the AV node of the heart upon which it acts via the AV node artery of the heart.
  • the composition is delivered in an antegrade fashion (direction which is the normal direction of blood flow) to the right coronary artery which feeds blood to the AV node artery.
  • the right coronary artery is the main vessel supplying blood to the right side of the heart and to the AV node.
  • the 1 st septal branch of the left anterior descending artery (which originates from the left coronary artery) may be the vessel which delivers blood to the AV node and can be selected as the delivery conduit for delivering the pharmaceutical composition to the AV node.
  • other possible routes of administration to the AV node may include Kugel's artery and the right superior descending artery.
  • the pharmaceutical composition can be delivered in a retrograde manner (direction which is opposite to the normal blood flow direction) through a coronary vein, such as the right or left coronary vein, to the AV node.
  • the pharmaceutical composition is delivered to the right coronary artery
  • one method to accomplish this drug delivery is to have an interventional cardiologist place the distal end of a drug delivery catheter within the right (or left) coronary artery via the femoral artery, or other peripheral artery, using standard fluoroscopic techniques.
  • Catheters such as intravascular catheters which are well known for use in diagnostic and therapeutic procedures can be used to administer the drug composition to the cardiovascular system, such as a standard Target Therapeutics TrackerTM (Boston Scientific) or Ultrafuse-X (Scimed Corporation) infusion catheter.
  • guide catheters are a well known form of catheter used to assist in the introduction of other catheters, guidewires and/or fluids to the arteriovenous system of a patient and can be used to facilitate proper catheter placement or drug delivery into the ostium of a coronary artery.
  • Such guide catheters typically are also designed specifically for percutaneous or surgical (cut-down) insertion through a femoral artery (or other peripheral vessel) in the groin area of the patient and advanced into the cardiovascular system with the aid of x-ray fluoroscopy.
  • Examples of such guide catheters are numerous with a few being disclosed in Pande U.S. Patent No. 4,596,563 and Macaulay et al. U.S. Patent No. 5,234,416.
  • the cardiac surgeons performing the complex cardiac surgical procedures on the heart, great vessels and/or other internal organs using the TransarrestTM procedure, for example, typically are not well trained in fluoroscopic techniques, and thus require the assistance of a cardiologist or other trained expert to place the drug delivery catheter in a fluoroscopically equipped cardiology lab prior to the procedure, which adds to the time, expense and complexity of the procedure.
  • the drug delivery system preferably should include one or more devices that can be easily placed by a surgeon into the thoracic cavity of a patient who may or may not be on CPB and while the heart is beating.
  • an infusion and/or guide catheter which is adapted to be introduced into a coronary ostium of a coronary artery of a heart of a patient through an opening in an aorta of the patient, without the aid of fluoroscopic guidance, for delivery of a fluid, such as a cardioplegia solution, or passage of a catheter, into the coronary artery while still permitting blood perfusion from the aorta into the ostium.
  • a fluid such as a cardioplegia solution, or passage of a catheter
  • the infusion catheter generally comprises a tube having at least one lumen, a proximal end, and a distal end, the tube having at least one bend to facilitate placement of the distal end of the tube into the ostium of the coronary artery when the proximal end of the tube extends from the opening in the aorta, wherein the distal end of the tube is configured to fit within the coronary ostium while still permitting blood perfusion from the aorta into the ostium.
  • the infusion catheter can be used as a system in conjunction with an intravascular catheter, an intraluminal shunt or similar drug delivery device which can be inserted directly into a coronary vessel, such as the right or left coronary artery, following cardioplegia administration through the infusion catheter.
  • an additional drug delivery apparatus and method is needed for surgeons who may not desire to reach the coronary artery through an opening in the aorta or through a peripheral access site.
  • One novel drug delivery approach is to deliver the pharmaceutical composition directly into the coronary artery by a direct injection surgical technique.
  • vascular wall such as an arterial wall
  • PTCA percutaneous transluminal coronary angioplasty
  • the majority of these devices require fluoroscopic techniques to advance and position the device within the patient's vasculature system.
  • these site-specific drug delivery systems include intravascular, fluoroscopic devices for site-specific (coronary artery) drug delivery comprising double-balloon catheters, porous balloon catheters, balloon-over-stent catheters, and stent devices, for example.
  • Epicardial drug delivery devices requiring surgical implementation have been developed which include drug-eluting polymer matrices and transpericardial patch devices.
  • Intramural injection of drug-eluting mircroparticles has been used as a drug delivery strategy following angioplasty. See, e.g., "Direct Intraarterial Wall Injection of Microparticles Via a Catheter: A Potential Drug Delivery Strategy Following Angioplasty, " Wilensky R., et al., AMER. HEART J., 122:1136, 1991. Intrapericardial injection of drugs has also been used for the treatment of malignant or loculated pericardial effusions in man. See, e.g., Igo et al. U.S. Patent No. 5,634,895.
  • Intraluminal shunts have been placed directly into coronary arteries, specifically the left anterior descending artery, to provide direct blood perfusion of the distal arterial lumen during the construction of coronary artery bypass grafts in a beating heart, such as the Rivetti-LevinsonTM Intraluminal Shunt (Heyer Schulte, Wisconsin). These shunt devices, however, are difficult to accurately place in a coronary vessel on a beating heart due to the constant translational motion of the vessel.
  • Intravascular catheters such as intravenous (IV) and intraarterial catheters
  • IV catheters are another well known form of catheter used for fluid or drug delivery directly into a vessel, usually from a peripheral access point such as through the skin of a patient.
  • These intravascular catheters generally comprise a flexible small diameter tube that is inserted into a patient's blood vessel to allow withdrawal or addition of fluid.
  • Typical peripheral IV catheters are used to gain access to a patient's venous system so the patient can be infused with medicaments, IV solutions or other fluids.
  • the proximal end of such a catheter usually includes a hub that is designed to be connected to a fluid supply line or other medical device such as a syringe or a valve or IV pump.
  • the cannula portion of these types of catheters e.g., the flexible fluid delivery portion at the distal end of the catheter which is configured to be inserted into and to reside within the vessel, is relatively short, e.g., on the order of about one inch long.
  • These peripheral IV catheters are typically placed in one of the patient's veins located in the hand or arm with the hub taped to the patient's skin.
  • Peripheral IV catheters may also include extension tubes, which are also generally relatively short in length and which extend proximally from the proximal end of the catheter generally coaxial with the cannula and which include a hub at the proximal end.
  • extension tubes which are also generally relatively short in length and which extend proximally from the proximal end of the catheter generally coaxial with the cannula and which include a hub at the proximal end. Examples of typical IV catheters are disclosed, for example, in Bujan U.S. Patent No. 3,064,648, Loper et al. U.S. Patent No. 3,589,361, Monestere U.S. Patent No. 3,851,647,
  • Intraarterial catheters are another form of intravascular catheter that are specifically adapted to be inserted into an artery. Because arteries are normally located deeper in the patient's tissue relative to the patient's skin than are veins, the cannula portion of an arterial catheter is normally longer than the corresponding cannula portion of IV catheters. Arterial catheters are typically used for blood pressure monitoring within an artery, as an introducer for other fluid delivery lines, and for other similar uses.
  • arterial catheters generally comprise a flexible cannula which is adapted to be inserted into the vessel, a catheter hub at the proximal end of the catheter, an extension tube extending coaxially with the cannula, and a retractable needle for making an opening in the vessel sized for insertion of the cannula.
  • intraarterial catheters can be found, for example, in Foti U.S. Patent No. 3,565,074, Kreuzer et al. U.S. Patent No. 5,1 16,323, and Purdy et al. U.S. Patent No. 5,797,882.
  • None of the previous devices are designed or are particularly well adapted to deliver a fluid or drug directly into a vessel subject to continuous translational motion, such as a coronary vessel on a beating heart.
  • a vessel subject to continuous translational motion such as a coronary vessel on a beating heart.
  • a device that allows for smooth and reliable insertion directly into a vessel within a patient's vasculature system even during constant translational motion of the vessel, while also minimizing the risk of trauma to the vessel interior lumen during insertion and placement.
  • the present invention satisfies those needs.
  • the present invention involves novel devices and methods for local, direct delivery of fluids or drugs, such as cardioplegia agents, to a vessel within a patient's vasculature system, such as a coronary vessel on a beating (non-arrested) heart of a patient, to facilitate cardiac and other surgical procedures.
  • a vessel within a patient's vasculature system such as a coronary vessel on a beating (non-arrested) heart of a patient
  • the invention facilitates surgical delivery of a cardioplegia agent to the coronary vasculature of the heart in the absence of fluoroscopic or other complex catheter guidance techniques.
  • a fluid delivery device of relatively simple construction for the direct, local delivery of a fluid or drug into a vessel within a patient's vasculature system which generally comprises an elongate cannula having a proximal end, a distal end, and at least one lumen extending between the proximal end and the distal end of the cannula; a connector coupled adjacent to the proximal end of the cannula defining at least a first lumen and a second lumen, wherein at least the first lumen extends coaxially with and is in fluid communication with the lumen of the cannula; an insertion needle having a sharp distal end, the needle being movably disposed lengthwise in the first lumen and the lumen of the cannula; and a flexible elongate tubular body having a proximal end and a distal end, the distal end of the tubular body being operatively coupled to and in fluid communication with the connector second
  • a fluid delivery device for the local, direct delivery of a fluid or drug into a vessel within a patient's vasculature system which generally comprises a support member having a proximal end portion and a distal end portion, and a fluid delivery member axially movably coupled to the support member, the fluid delivery member having a fluid delivery portion and being axially moveable relative to the support member between a first position in which the fluid delivery portion extends outside of the vessel, and at least one second position in which the fluid delivery portion is adapted to be inserted into the vessel through an opening in the vessel.
  • the support member supports the fluid delivery member in its first position and preferably is configured to stabilize a tissue surface on or near the vessel to facilitate insertion of the fluid delivery member (or a portion thereof) into the vessel.
  • the configuration of the support member and the fluid delivery member can take many forms.
  • the support member includes a stabilizing means for retaining the distal end portion of the support member relatively immobile with respect to a surface of the vessel, such as a coronary artery on a beating heart.
  • the support member includes an elongated tubular body to which the fluid delivery member is movably coupled.
  • the wall of the elongated tubular body defines an inner lumen which is adapted to be coupled to a vacuum source for effecting a suction force at a distal end of the tubular body.
  • the support member may also further include at least one tissue contact member coupled to a distal end portion of the tubular body which is shaped to engage a tissue surface on at least one side of the vessel.
  • the fluid delivery device can include two contact members shaped as planar feet which are located in a parallel orientation with respect to each other and which are adapted to engage a tissue surface on either side of the vessel to aid the surgeon in aligning the device with the longitudinal aspect of the vessel to thereby facilitate insertion of the fluid delivery member into the vessel.
  • the fluid delivery member may be both slidably and removably coupled to the elongated tubular body so that it can be moved axially relative to the tubular body and removed therefrom to permit fluid infusion into the vessel.
  • the fluid delivery member generally comprises a cannula portion, a hub member coupled to the proximal end of the cannula portion, and a needle insertion assembly which is slidably coupled to the cannula portion and the hub member.
  • the hub member is configured to be slidably received within a longitudinal channel extending axially along an external surface of the distal end portion of the elongated tubular body.
  • the hub member is releasably fixed to the channel in the first position of the fluid delivery member and is configured to be moved axially along the length of the tubular body when the stabilizing means holds the fluid delivery device adjacent to or near the surface of the vessel.
  • the needle insertion assembly is used to make a small opening, or incision, in the vessel to permit the cannula portion of the fluid delivery member to be inserted therein for fluid delivery.
  • the hub member further preferably includes a pair of spaced-apart suture wings located on either side of the hub member through which a conventional suture(s) can be tied to secure the fluid delivery member proximate the vessel following removal of the needle insertion assembly from the hub member and separation of the fluid delivery member from the tubular body.
  • the support member may include one or more actuator mechanisms which is/are adapted to vary the incident angle and/or to control the depth at which the cannula portion of the fluid delivery member is inserted into the vessel. This may be important to provide the practitioner with greater control over the needle insertion assembly to prevent it from inadvertently piercing through the wall of the target vessel opposite the insertion site during insertion and placement of the cannula portion of the fluid delivery member into the vessel.
  • the fluid delivery device may also be specially adapted to deliver a fluid or drug to an anastomosis site prior or during the creation of an anastomosis graft.
  • the intended target vessel for fluid or drug administration such as the right coronary artery
  • a further alternative embodiment of the invention which is particularly well-adapted to administer a fluid or drug to an anastomosis site in a vessel is disclosed which generally includes a fluid delivery member in the form of an intraluminal shunt-type member which is sized and dimensioned to be conformably and slidably received about an intravascular catheter having an elongated tubular body which acts as a support member to support the shunt.
  • a needle stylet assembly is removably coupled to a central lumen within the elongated tubular body and is used to make an opening, or small puncture, in the vessel wall.
  • a fluid such as a novel cardioplegia agent(s) which is capable of inducing reversible ventricular asystole of the heart while maintaining the ability of the heart to be electrically paced (for example, an AV node blocker compound and a beta blocker compound), can then be delivered through the lumen to induce ventricular asystole in the heart.
  • a novel cardioplegia agent(s) which is capable of inducing reversible ventricular asystole of the heart while maintaining the ability of the heart to be electrically paced
  • AV node blocker compound and a beta blocker compound for example, an AV node blocker compound and a beta blocker compound
  • a larger arteriotomy incision can be made in the stationary vessel around the needle puncture site with a standard scalpel or other appropriate cutting instrument.
  • the shunt-type member can then be moved axially along the external surface of the tubular body and removed therefrom as it is inserted into the motionless coronary vessel.
  • the shunt-type member offers the advantage of providing a blood-free anastomosis area for performing an anastomosis to the target vessel at the site of fluid or drug delivery.
  • the shunt-type member can also be used to administer a fluid or drug, such as a novel cardioplegia solution (e.g., a cholinergic agent solution, e.g., carbachol) to the vessel which is capable of maintaining ventricular asystole during the duration of the surgical procedure (as described above), if necessary.
  • a novel cardioplegia solution e.g., a cholinergic agent solution, e.g., carbachol
  • the shunt- type member maintains a relatively low-profile within the vessel and thereby permits the surgeon to perform the anastomosis graft in a substantially unobstructed surgical field.
  • the shunt type-member preferably includes a removable grip portion which can be used to guide the shunt-type member axially along the external surface of the tubular body.
  • the grip portion can include one or more suture holes through which a conventional suture(s) can be tied to secure the shunt-type member proximate the vessel during fluid delivery through the lumen of the main tubular body.
  • the grip portion can preferably be removed from the shunt-type member prior to insertion of the shunt-type member into the vessel.
  • several methods for directly delivering a fluid or drug to within a coronary vessel on a beating heart which in one representative embodiment generally includes providing a fluid delivery device, stabilizing a tissue surface of the heart proximate to or on the coronary vessel near where an opening in the coronary vessel is to be made, making an opening in the coronary vessel, and delivering a fluid into the coronary vessel through the opening with the fluid delivery device.
  • the method can include, for example, aligning the distal end portion of the fluid delivery device with the longitudinal aspect of the vessel.
  • the stabilizing includes retaining a distal end portion of the fluid delivery device in abutting engagement with the surface of the coronary vessel by applying a suction force to the surface of the coronary vessel near the distal end portion.
  • the retaining can also include applying proximal finger pressure on either side of the vessel to minimize its motion.
  • the delivering a fluid can include axially moving a fluid delivery member relative to the device to thereby insert a cannula portion of the fluid delivery member into the vessel.
  • the making an opening in a vessel can include making an opening in a coronary vessel selected from the group consisting of a right coronary artery, a left main coronary artery, a left anterior descending artery, a left circumflex artery, a proximal coronary artery, and any branches thereof.
  • the device may also be used to administer (or withdraw) a fluid from other blood vessels and body organs.
  • Figure 1 is side elevational view of a first embodiment of a fluid delivery device constructed in accordance with the principles of the present invention.
  • Figure 2 is a perspective view of the device of Figure 1 being inserted into a right coronary artery on the heart of a patient for its intended application.
  • Figure 3 is a side elevational view showing the patient's thoracic cavity with the extension tube portion of the fluid delivery device extending outside the thoracic cavity.
  • Figure 4 is an enlarged perspective view of the heart of the patient of Figures 2 and 3 showing the fluid delivery device being inserted into the right coronary artery.
  • Figure 5 is a side elevational view of an alternative embodiment of the invention which is particularly well-adapted to administer a fluid or drug to the site of an anastomosis in a coronary vessel (such as the right coronary artery) which generally includes a support member in the form of an intravascular catheter and a fluid delivery member movably coupled to the support member which is in the form of a shunt.
  • a coronary vessel such as the right coronary artery
  • Figure 6 is a perspective view showing the device of Figure 5 being inserted into a right coronary artery of a patient's heart.
  • Figure 7 is a side-elevational view of the device of Figure 6 prior to removal of the needle insertion assembly therefrom.
  • Figure 8 is a side-elevational view of the device of Figure 7 following removal of the needle insertion assembly therefrom.
  • Figure 8 A is a detailed, enlarged view of the shunt member of the device of Figure 7 shown secured to a tissue surface of the heart proximate the vessel.
  • Figure 9 is a side-elevational view of the device of Figure 8 A showing an arteriotomy incision being made in the vessel at the fluid delivery device insertion site following removal of the grasping flange from the shunt member.
  • Figure 10 is a side-elevational view showing the shunt member fully inserted into the vessel following removal of the intravascular catheter portion of the fluid delivery device from the operative site.
  • Figure 11 is a perspective view of an alternative embodiment of a fluid delivery device constructed in accordance with the principles of the present invention which includes a support member and a fluid delivery member movably coupled thereto, the support member being adapted to stabilize and/or align a region of the vessel near where an opening in the vessel is to be made prior to insertion of the fluid delivery member into the vessel.
  • Figure 11 A is a side-elevational view of the fluid delivery member which is movably coupled to the fluid delivery device of Figure 11.
  • Figure 12 is a transverse cross-sectional view of the distal end portion of the support member of the fluid delivery device of Figure 11.
  • Figure 12A is a bottom-end view of the distal end portion of the support member of the fluid delivery device of Figure 11.
  • Figure 13 is a perspective view of the proximal end portion of the support member of the fluid delivery device of Figure 11.
  • Figure 13A is a transverse cross-sectional view of the proximal end portion of the support member of the fluid delivery device of Figure 11.
  • Figure 14 is a perspective view of an alternative embodiment of a fluid delivery device constructed in accordance with the principles of the present invention which includes a support member and a fluid delivery member movably coupled thereto, wherein the support member can be manipulated to control the incident angle and the penetration depth at which the fluid delivery member is inserted into the vessel.
  • Figure 15A is a front-side elevational view of the fluid delivery device of Figure 14.
  • Figure 15B is a rear-end elevational view of the fluid delivery device of Figure 14.
  • Figure 15C is a perspective rear-end elevational view of the fluid delivery device of Figure 14.
  • the present invention relates generally to apparatus and methods for the direct delivery of fluids or drugs, such as cardioplegia agents, into a vessel within the vasculature system of a patient.
  • the present invention is particularly well suited for directly delivering a cardioplegia agent to within a coronary artery on a beating heart, such as the right coronary artery, during the course of a surgical procedure, such as a coronary artery bypass graft procedure.
  • the devices of the present invention allow a physician to place the devices within a vessel, such as a coronary vessel, without fluoroscopy and with minimal trauma to the vessel endothelium.
  • the devices of the present invention are particularly well-adapted for delivery of a fluid or drug to within a vessel subject to constant translational motion, it is to be understood that the devices can be used to administer a fluid or drug into any vessel or other body organ within a patient.
  • the devices of the present invention can be used to pass an intravascular device into the vessel, such as a stent or a shunt, for example.
  • FIG. 1 depicts a first embodiment of a fluid delivery device 10 constructed in accordance with the principles of the present invention.
  • the fluid delivery device 10 very generally includes a relatively low-profile cannula portion 20, a soft, atraumatic Y-shaped connector 30 coupled to a proximal end portion of the cannula portion 20, an insertion needle assembly 40 which extends lengthwise through the connector 30 and cannula portion 20, and a flexible extension tube 50 which is fluidly coupled to connector 30 and cannula portion 20.
  • Cannula portion 20 has a single lumen extending therethrough.
  • cannula portion 20 could also include two lumens extending therethrough, a first lumen dedicated for the insertion needle assembly 40 and a separate dedicated lumen fluidly coupled to extension tube 50.
  • Cannula portion 20 has a length "d" shown in the drawings which preferably tapers slightly towards the distal tip 22 of the cannula portion to facilitate insertion into a selected vessel.
  • the distal tip 22 of cannula portion 20 is preferably smooth and slightly rounded as shown to prevent vessel trauma during device insertion and placement.
  • the cannula portion 20 preferably has a sufficient length and rigidity to extend generally coaxially within a vessel, such as a coronary artery, and to substantially retain its position therein without backing out of the vessel after it is inserted therein.
  • the cannula portion 20 should have a length of at least about 20 mm, preferably between about 20 to 50 mm, and more preferably between about 40 and 50 mm, to adequately maintain its position within the vessel.
  • the cannula portion 20 must also be configured to reside in the vessel, such as a coronary artery, without any significant decrease in the blood flow through the vessel.
  • the coronary arteries are very small and typically have a diameter in the range of between about 1 to 5 mm.
  • the outside diameter of the cannula portion 20 must also be sufficiently small so as not to cause trauma to the vessel during device insertion and placement and to allow for adequate blood perfusion about the cannula portion 20 after it is inserted into the vessel.
  • the outside diameter of cannula portion 20 thus should be about 1 mm or less.
  • the configuration of the cannula portion 20 can vary depending on the size of the vessel into which it is inserted.
  • Cannula portion 20 may be formed of polymeric materials such as polyurethane, polyethylene, polyvinylchloride and the like, and any suitable combinations thereof.
  • Cannula portion 20 can be formed of a hydrophilic polyurethane that softens when exposed to physiological conditions (e.g., about 37° aqueous saline or blood). Cannula portion 20 can also be provided with additional materials to add strength, stiffness and/or flexibility to the cannula portion 20.
  • cannula portion 20 may include a relatively thick- walled braided or wound wire matrix (e.g., made from stainless steel) to provide overall stiffness to the cannula portion 20. By varying the pitch of the braided or wound wire, the steerability of the cannula portion 20 can be modified along its length. The relative thickness of the cannula portion 20 may vary depending on the use of the device and the vessel anatomy into which it is placed.
  • Connector 30 is fixedly attached to the proximal end of cannula portion 20.
  • Connector 30 includes two lumens 32 and 34.
  • Lumen 32 extends generally coaxially with and is fluidly coupled to the internal lumen within cannula portion 20.
  • Lumen 32 is sized to releasably receive insertion needle assembly 40 therein.
  • Bonded to the proximal end of lumen 32 is a standard flow control plug, or grommet, 33 which seals the inlet opening to lumen 32 following removal of needle insertion assembly 40.
  • Flow control plug 33 is made from conventional plastic materials such as silicone or latex, preferably silicone, and is preferably located flush with the proximal end of the lumen 32 or may be recessed slightly therefrom.
  • lumen 32 may be provided with a hemostasis valve member in lieu of flow control plug 33.
  • a hemostasis valve member may be employed including a Touhy Borst valve, ball valve, spool valve, poppet valve, diaphragm valve, duck-bill valve, and the like, preferably a Touhy Borst valve.
  • Lumen 34 is also fluidly coupled to the internal lumen within cannula portion 20 and is in fluid communication with a central lumen extending through extension tube 50.
  • a Y-shaped connector 30 located immediately adjacent to cannula portion 20 has several advantages.
  • the Y-shaped connector 30 allows extension tube 50 (which among other things provides strain relief for the device 10) to be spaced- apart and separated from insertion needle assembly 40.
  • extension tube 50 which among other things provides strain relief for the device 10.
  • insertion needle assembly 40 does not need to be configured to extend along a lengthy extension tube and can be made shorter than is typical for most IV or intraarterial catheters.
  • the practitioner can manipulate it near to the intended target vessel, which is important for surgeons who are used to manipulating instruments near the operative site typically under the assistance of magnification headwear.
  • locating the needle insertion assembly 40 separately from the main extension tube 50 of the device has the advantage of preventing kinking of the extension tube 50 during retraction and removal of the needle thereby facilitating needle retraction.
  • Connector 30 preferably has a low-profile cross-section which has a generally circular or oval configuration.
  • any other low profile shape such as an elliptical shape or a generally rectangular shape could also be used.
  • the oval configuration avoids sharp corners so that connector 30 minimizes trauma to the heart or vessel when it is secured proximate thereto.
  • the low-profile of connector 30 also ensures that no substantial portion of device 10 substantially obstructs the surgical field in which the surgeon operates, which is particularly important when the device 10 is used to deliver a fluid to a coronary vessel, such as the right coronary artery, at or near the site of an anastomosis.
  • Connector 30 may include one or more suture holes 35 therein which allow the connector to be stably sutured to a tissue surface of the heart proximate the intended target vessel, for example. Preferably, there is one suture hole 35 on either side of connector 30.
  • other means to secure the connector 30 proximate the vessel can be employed as well, such as, for example, applying an adhesive to the lower surface of the connector 30, such as cyanoacrylate, e.g., Loctite®, manufactured by Loctite Corporation (Hartford, CT), or other bonding materials.
  • the adhesive is preferably compatible with biological tissue surfaces and the like and should be capable of easily being flaked off of the tissue surface following removal of the connector therefrom.
  • Connector 30 may be made from a suitable relatively soft plastic material such as polyurethane and may have a substantially planar bottom surface or a curved bottom surface to conform to the topical surface of the heart, a vessel, or other tissue conformation.
  • the connector 30, due to its inherent flexibility, preferably can be manipulated to substantially conform to the topical surfaces of the heart to which it is secured.
  • flexible connector 30 could also comprise a laminate structure formed by an upper paper or other woven or non-woven cloth layer, an inner cellulose foam layer, and a bottom adhesive layer.
  • connector 30 may comprise only an adhesive bottom layer and an upper cellulose foam layer.
  • the cyanoacrylate bottom surface of connectro 30 may include a removable backing (e.g., of paper or plastic) covering it before use, which can then be peeled away to expose the adhesive surface.
  • the backing prefereably resists tearing and may be divided into a number of pieces to ease attachement of the connector 30 to the heart.
  • Insertion needle assembly 40 includes an elongate, non-coring beveled insertion needle 42 having a proximal end portion 44, a distal end portion 46 and a central hollow bore passageway therethrough. Insertion needle 42 is sized to fit within and to extend coaxially with lumen 32 of connector 30 and the central lumen through cannula portion 20. Insertion needle 42 has a clear, transparent hub 48 attached to the proximal end portion 44 of the needle and a sharpened tip 49 at the distal end of the needle 42.
  • Needle 42 has a sufficient length so that sharpened tip 49 of needle 42 is capable of extending beyond the distal tip 22 of cannula portion 20 when insertion needle assembly 40 is disposed within lumen 32 and the lumen through cannula portion 20.
  • the device 10 may also be provided with a shield (not shown) that releasably fits over needle 42 and cannula portion 20 to protect the projecting needle tip 49 of the device 10.
  • Needle hub 48 is preferably formed from a thermoplastic material that is substantially transparent or at least translucent, so that the presence of fluid, such as blood, is visible in the hub.
  • Thermoplastic materials such as polycarbonate, polypropylene, and polyamide are suitable for forming hub 48.
  • the flexible extension tube 50 includes a proximal end portion 52, a distal end portion 54, and a conventional luer adapter 56 which is configured to easily connect with other fluid carrying members such as a syringe or a valve or IV pump.
  • Extension tube 50 also includes a central lumen therethrough and is formed from a soft, flexible material such as silicone.
  • Extension tube 50 preferably has a sufficient length and flexibility to extend outside of the thoracic cavity (or other applicable body cavity depending on the application) when the cannula portion 20 is inserted into a coronary vessel on the heart, for example.
  • the length of extension tube should be at least about 100 mm or greater, for example between about 125 to 175 mm, for example about 150 mm.
  • the relatively long length of extension tube 50 serves several important functions.
  • the long extension tube 50 provides optimal strain relief to the device 10 to prevent the cannula portion 20 from pulling out of the vessel.
  • the lengthy tubing also allows other fluid delivery members (such as an IV pump and the like) to be coupled to the device 10 far removed from the operative site, which minimizes trauma to the vessel from abrasion resulting from continuous movement of the extension tube adapter 56, fluid carrying members coupled thereto, and extension tube 50, when the connector 30 is secured in place adjacent to the vessel.
  • the relatively long length of the extension tube 50 also allows the tube to be secured to the chest cavity (or to a surgical retractor placed therein which separates the ribs to provide access to the chest cavity) away from the operative site.
  • the extension tube 50 may optionally include an anchor 57 (shown in phantom) fixed to the proximal end portion 52, such as an alligator clip for example, or similar fixation member, to removably attach the device 10 to a surgical retractor used to spread the ribs to provide direct access to the thoracic cavity, such as any of the surgical thoracic cavity retractors disclosed in U.S. Patent Nos. 4,726,356, 4,829,985, and 5,025,779, the entire contents of which are expressly incorporated by reference herein.
  • the tube 50 may be attached to a fixed support other than a fixture on a retractor system such as the surgical table or the chest cavity of the patient (using one or more purse string sutures, for example).
  • the device 10 may optionally be provided with a thin wire (not shown) which can be slidably received within the needle bore through needle 42.
  • needle 42 may be removed over the wire following insertion of the cannula portion 20 partially into the vessel leaving the small wire extending a short distance beyond the distal tip 22 of cannula portion 20.
  • the thin wire can then be extended further into the vessel and can serve as a steering or guiding mechanism to help direct the passage of the cannula portion 20 further into the vessel, if necessary.
  • cannula portion 20 can be provided with some form of illumination capability, such as a small light-emitting diode (LED) located near the distal tip 22 of the cannula portion, to aid the practitioner in visualizing the progress of the cannula portion 20 as it is inserted deeper into the vessel, similar to the techniques for vessel illumination disclosed in copending, commonly-assigned CIP patent application for "Fluid Delivery Apparatus and Methods," filed on May 14, 1999 and bearing Attorney's Docket No. 35353-20010.20.
  • LED small light-emitting diode
  • the cannula portion 20 could be illuminated in a variety of other ways, including passing an optical fiber (not shown) through a dedicated lumen in the cannula portion 20 until a light delivery portion of the optical fiber resides near the distal tip 22 of the cannula portion 20.
  • the optical fiber could be illuminated with a conventional white light source, laser source, or by other similar means from outside the patient to provide a visual indication of the presence of the cannula portion within the vessel.
  • the optical fiber could be secured in place to cannula portion 20 through the use of a Touhy-Borst valve, or similar valve member, coupled to one of the lumens of connector 30 as described above.
  • cannula portion 20 may also be provided with one or more ring electrodes (not shown) to facilitate positioning of the cannula portion proximate to the AV node artery, for example, similar to the techniques for catheter positioning disclosed in commonly-assigned CIP patent application for "Fluid Delivery Apparatus and Methods," filed on May 14, 1999 and bearing Attorney's Docket No. 35353-20010.20.
  • the one or more electrode rings would be used to sense electrical signals generated by a pacemaker node of the heart (such as the AV node or, in some cases, the SA node).
  • the respective electrode rings can be used in conjunction with a conventional EKG machine for endocardial mapping as is known in the art.
  • the one or more ring electrodes can provide the practitioner with a nonvisual indication of where the distal portion of the cannula portion 20 is located with respect to the AV node artery, for example, by monitoring the electrical activity of the AV node. In this way, fluid or drug delivery can be accurately targeted to the region of the vessel which is located proximal the intended target vessel (i.e., the AV node artery) based on the recorded electrical signals of the pacemaker node (e.g., the AV node).
  • FIG. 1 The operation of the device 10 of Figure 1 for inducing reversible ventricular asystole in the heart of a patient to facilitate a cardiac or other surgical procedure will now be described with reference to Figures 2-4.
  • the methods herein described are used in an open chest coronary artery bypass graft surgical procedure where the surgeon gains access to the heart via a partial or median sternotomy by severing the sternum, or a portion of it, along its longitudinal midline to expose the thoracic cavity.
  • a cardioplegia solution such as a pharmaceutical composition including an AV node blocker and a beta blocker, can then be delivered to the coronary vasculature with the device 10 of the present invention to induce reversible ventricular asystole.
  • the methods described herein are illustrative only and in no way limit the variety of procedures in which the apparatus of the present invention can be used.
  • MIDCAB or OPCAB
  • the mini- thoracotomy incision may be intercostal or parasternal but is preferably performed intercostally, and preferably on the second, third, fourth or fifth intercostal spaces, and most preferably on the fourth or fifth intercostal spaces.
  • fluid delivery device 10 and related devices of the present invention are particularly well suited to facilitate a TransarrestTM procedure, as described above and below, the systems and devices are not limited to their use in a TransarrestTM procedure, and can be used to facilitate any medical or surgical procedure in which it is required to deliver a therapeutic, diagnostic, or other pharmacologic agent into any vessel within a patient's vasculature system.
  • non-limiting uses of fluid delivery device 10 include delivery of contrast media, e.g., radio-opaque agents, into the coronary vasculature for viewing blood vessel anatomy and blood flow characteristics in a target region, such as at an anastomosis site.
  • fluid delivery device 10 could be used in other situations to locally administer to the coronary vessels of the heart one or more of a wide variety of therapeutically useful pharmacologic agents to prevent thrombus formation, smooth muscle cell proliferation, or inflammatory responses at an anastomosis site or in a stenosed region of a diseased vessel.
  • therapeutically useful pharmacologic agents include anti- platelet or anti-thrombus agents (such as Heparin, Hirudin, tPA, Streptokinase, Urokinase, Persantine, Aspirin, etc.), anti-inflammatory agents (such as steroidal and non-steroidal compounds), and anti-proliferative compounds (such as suramin, monoclonal antibodies for growth factors, and equivalents).
  • drugs can be administered into the coronary vasculature to facilitate healing and reduce the incidence of thrombosis at an anastomosis site, such as immunosuppressant agents, glycosaminoglycans, collagen inhibitors, and endothelial cell growth promoters.
  • the device 10 can also be used to deliver other therapeutic or diagnostic agents to other vessels and/or body organs within a patient and also can be used to pass other intravascular devices into a vessel, such as a stent, for example, or a clotting wire or other therapeutic or diagnostic device.
  • FIG. 1 An exemplary use of the device 10 of the present invention for inducing reversible ventricular asystole in the heart during an open chest surgical procedure is presented.
  • the patient undergoing the procedure such as a coronary artery bypass graft procedure, is prepared according to known techniques for conventional open chest surgery.
  • the heart 70 and its main vessels are exposed following a median sternotomy.
  • a detailed view of the heart is shown in Figure 4.
  • heart 70 includes aorta 72 which receives blood pumped from the left ventricle and delivers it to the major organs of the body.
  • coronary ostia 74 and 76 Communicating with the aorta are coronary ostia 74 and 76 which are the respective inlet openings to the right 75 and left 77 coronary arteries, respectively.
  • the right coronary artery 75 branches at its distal segment into the posterior descending artery 79 and the circumflex branches.
  • the atrioventricular node artery 81 feeds blood to the AV node (not shown for clarity).
  • a source of arterial blood be prepared for subsequent bypass connection to the diseased artery.
  • An arterial graft can be used to provide a source of blood flow, or a free vessel graft may be used and connected at the proximal end to a source of blood flow.
  • the source of blood flow is any one of a number of existing arteries that are dissected in preparation for the bypass graft procedure. In many instances, it is preferred to use either the left or right internal mammary artery.
  • free graft vessels such as the saphenous vein, gastroepiploic artery in the abdomen, and other arteries harvested from the patient's body as well as synthetic graft materials, such as DacronTM or Gore-TexTM grafts. If a free graft vessel is used, the upstream end (proximal) of the dissected vessel, which is the arterial blood source, will be secured to the aorta to provide the desired bypass blood flow, and the downstream end (distal) of the dissected vessel will be connected to the target vessel in a distal anastomosis.
  • the surgeon identifies a target region in the right (or left) coronary artery 75,(77) where drug delivery is to occur.
  • the surgeon may use one or more purse-string sutures in the pericardial sac placed under the heart to lift and rotate the heart.
  • the selection of the right 75 versus left 77 coronary artery is dependent upon pre-operative angiographic confirmation of the blood supply route to the AV node.
  • the right coronary artery 75 is the main vessel supplying blood to the right side of the heart and to the AV node.
  • the 1 st septal branch of the left anterior descending artery (which originates from the left coronary artery 77) may be the vessel which delivers blood to the AV node and can be selected as the delivery conduit for delivering the pharmaceutical composition to the AV node.
  • other possible routes of administration to the AV node may include Kugel's artery and the right superior descending artery. The exact location for fluid delivery along the length of the vessel chosen is dependent on a number of factors, including accessibility of the target site on the vessel, its visibility, and the degree of disease in the vessel (if any).
  • the vessel has a stenosed region therein, it is preferable to deliver the drug to a portion of the vessel distal to the stenosis and as close as possible to the right coronary artery's 75 bifurcation to the posterior descending artery 79. This will ensure that the majority of the drug reaches the AV node artery 81 and does not bypass the AV node artery 81 via the larger posterior descending artery 79 or other collateral vessels.
  • the target vessel is one of the coronary arteries that needs to be bypassed, the surgeon will chose a fluid administration site that is also the location for an anastomosis graft to the artery to minimize the number of vessel punctures.
  • the surgeon prepares the target location on the right coronary artery 75 by removing fat tissue and the like to expose the external surface of the vessel. With the right coronary artery 75 partially exposed in the target region, the surgeon stabilizes the heart on opposite sides of the vessel by applying proximal finger pressure to the heart surface on either side of the vessel.
  • conventional mechanical stabilizers which have planar surfaces designed to atraumatically grip the epicardium surface of the heart, can be used by the surgeon to stabilize the heart region surrounding the vessel, such as the OctopusTM suction stabilizer device from Medtronic (Minneapolis, Minnesota).
  • the surgeon then makes a small puncture in the vessel with needle insertion assembly 40 until a small backflash of blood is visualized through the needle hub 48.
  • the cannula portion 20 is then advanced a short distance into the artery.
  • the surgeon then removes needle insertion assembly 40 in a generally straight continuous motion to prevent kinking of the cannula portion 20.
  • surgeon may now thread one or more sutures through the suture hole(s) 35 provided in connector 30 to secure the connector 30 to the heart to prevent substantial movement of cannula portion 20 relative to the vessel.
  • the extension tube 50 is grasped by the surgeon or surgeon's assistant and secured to the retractor 60 or similar fixed structure such as the surgical table or chest wall.
  • the extension tube may be secured to the chest cavity using a clip 57 attached to the extension tube or similar fixation mechanism.
  • the adapter hub 56 of extension tube 50 can then be connected to a conventional fluid carrying member such as an IV pump or syringe for delivery of a fluid or drug to the vessel.
  • a liquid containing a cardioplegia solution is directed through the fluid delivery device 10 and into the artery 75.
  • the preferred cardioplegia solution is a pharmaceutical composition which is capable of reversibly inducing ventricular asystole in the heart while maintaining the ability of the heart to be electrically paced.
  • the procedure is fully detailed in "Compositions, Apparatus and Methods For Facilitating Surgical Procedures," Serial No. 09/131,075, filed August 7, 1998 and invented by Francis G. Duhaylongsod, M.D, the entire contents of which are expressly incorporated by reference herein.
  • the pharmaceutical composition comprises an AV node blocker compound such as carbachol and a beta blocker compound such as propranolol.
  • the beta-blocker propranolol and the AV node blocker carbachol can be provided as a single kit in separate pharmaceutically acceptable closed carriers and serially administered as an initial intracoronary bolus to induce reversible ventricular asystole of the heart.
  • carbachol is provided in a pharmaceutically acceptable carrier suitable for intracoronary administration.
  • the carbachol may be provided in an aqueous carrier, such as water or saline.
  • the concentration of carbachol may range, for example, from about 0.01 mg/ml to 2.55 mg/ml, e.g., about 0J to 1.0 mg/ml.
  • propranolol may be provided in a separate pharmaceutically acceptable carrier at a concentration of about 0.5 to 6.0 mg/ml, e.g., about 0.5 to 3.0 mg/ml, or about 1.0 to 2.0 mg/ml, or about 1.0 mg/ml.
  • the bolus injection of propranolol and carbachol can be administered by connecting adapter hub 56 to a standard infusion pump assembly fluidly coupled to the respective compounds and directing the compounds through the assembly into the vessel.
  • a standard infusion pump assembly fluidly coupled to the respective compounds and directing the compounds through the assembly into the vessel.
  • an intracoronary injection of 0.5 to 4 mg, for example about 1 mg, of propranolol is administered by intracoronary infusion over a time period of about 0.5 to 3.0 minutes, e.g., about 1 minute, preferably followed by a saline flush, such as 2 mL saline flush.
  • a cardioplegia solution is delivered through the device 10 at an infusion rate sufficient to maintain reversible ventricular asystole by periodic (e.g., one or more bolus infusions) or continuous infusion.
  • carbachol is administered as a continuous intracoronary infusion through the infusion catheter 10 at a rate of about 0.01 to 0.3 mg/min, e.g., about 0.025 to 0.3 mg/min, for example, about 0.01 to 0J mg/min, e.g., about 0.05 to 0J mg/min, e.g., about 0.0825 mg/min, for a time period of about 5 to 90 minutes, preferably about 30 to 90 minutes, depending on the length of the procedure.
  • Carbachol can also be administered as a series of bolus injections through device 10 to maintain reversible ventricular asystole.
  • An intravenous dosage of about 1.0 mg of phenylephrine can be systemically administered to the patient to control any hypotensive effects associated with carbachol administration.
  • atropine about 1 mg
  • Intracoronary nitroglycerine e.g., about 200 meg
  • the heart With the heart in controlled ventricular asystole, the heart is appropriately prepared for the anastomosis procedure (or other cardiac or other surgical procedure). Electrical pacing wires are connected to the right ventricle and/or left ventricle and/or atria and are used to pace the heart using a novel foot-actuated pacer control system (as fully described in the co-pending TransarrestTM patent application Serial No. 09/131,075) to maintain the patient's blood circulation during the periods in which the surgeon is temporarily not performing the surgical procedure.
  • a novel foot-actuated pacer control system as fully described in the co-pending TransarrestTM patent application Serial No. 09/131,075
  • the surgeon can control the pacing of the heart with a convenient foot pedal and can controllably stop the heart as sutures are placed in the vessel walls.
  • the procedures with which the systems and methods of the present invention are useful include coronary bypass surgery (with full or partial sternotomy or thoracotomy), transmyocardial laser revascularization, tachyarrythmia operations such as electrophysiology lab procedures (diagnostic and therapeutic ablation of arryhthmias), imaging procedures of the heart and great vessels such as CAT scan or MRI procedures, percutaneous transluminal coronary angioplasty, placement of stents such as coronary or aortic stents, operations where uncontrollable hemorrhage is present or anticipated or control of significant hemorrhage is required during the surgical procedure (for example, treatment of injuries to the liver, spleen, heart, lungs, or major blood vessels, including iatrogenic and traumatic injuries to such organs or structures), other procedures including percutaneous aortic aneurysm graft placement, neurosurgical procedures, such as aneurysm repair, and various other procedures that would benefit from the inducement of ventricular as
  • the devices and methods of the present invention provide a convenient mechanism to administer pharmaceutical compositions to the heart to arrest the heart and thereby provide a motionless field in which to operate, whether a surgeon uses conventional surgical techniques or emerging robotically-assisted techniques.
  • the device 110 is particularly well-suited for directly delivering a fluid or drug, such as the above-described pharmaceutical compounds, to the site of an anastomosis in a coronary vessel, such as the right coronary artery, for example, prior to or during the creation of an anastomosis graft.
  • a fluid or drug such as the above-described pharmaceutical compounds
  • the intended target vessel for fluid or drug administration may also have a stenosed region therein which needs to be bypassed to provide blood flow to the distal portion of the vessel and any collateral vessels connected thereto. It would be advantageous, therefore, to provide a fluid delivery device that can be inserted into the anastomosis site (to avoid multiple punctures in the vessel) and which has a low-profile to provide the surgeon with a clear surgical field in which to perform the anastomosis graft.
  • Fluid delivery device 110 solves that problem and provides a convenient mechanism to deliver a fluid or drug into a vessel at the site of an anastomosis.
  • the device 110 comprises an intravascular catheter 111 which includes a flexible, elongate extension tube 112 having proximal and distal end portions 114 and 116, respectively.
  • the proximal end portion 114 of the catheter 111 includes a conventional Y-shaped adapter hub 118.
  • Adapter hub 118 includes a first arm 120 through which a retractable needle assembly 124 is slidably received.
  • Second arm 121 of Y-shaped adapter 118 is conventional in the medical field for making connections with other fluid carrying tubular members and includes a standard luer fitting 123 which can be used for connecting with fluid infusion tubing, such as IV catheter tubing, and the like for administering a fluid into arm 121.
  • Needle assembly 124 is conventional, such as is commercially available from
  • Becton-Dickinson (Sandy, Utah) under the trademark name Angio-SetTM , and generally comprises a non-coring, beveled needle, a generally transparent needle hub at its proximal end, and a stainless steel wire (not shown) coupling the needle to the needle hub.
  • a standard flow control plug 125 can be configured to be secured to the proximal end of arm 120 to seal the inlet opening to arm 120 following removal of needle assembly 124 (See
  • Flow control plug 125 is made from conventional plastic or elastomeric materials such as silicone or latex, preferably silicone.
  • hub 1 18 can include a clip (not shown), such as an alligator clip for example, or similar fixation member to removably attach the hub 118 to a surgical retractor, or other relatively stationary structure.
  • Elongated extension tube 112 defines an internal fluid delivery lumen through which a drug or other fluid passes. The fluid delivery lumen extends from adapter hub 118 through tube 112 and through the distal end portion 116 to a distal opening (not shown).
  • the distal end portion 116 of the catheter includes a fluid delivery portion 115 which has a similar configuration to cannula portion 20 described previously.
  • the intravascular catheter 111 also includes a fluid delivery member 130 which is adapted to be inserted into the vessel through an opening in the vessel following drug administration through extension tube 112 (as will be explained in greater detail below) for subsequent fluid or drug administration into the vessel while also maintaining blood perfusion through the vessel.
  • Fluid delivery member 130 is in the form of an intraluminal shunt 132.
  • the shunt 132 may be similar to a shunt available from Heyer-Schulte NeuroCare Group (Pleasant Prairie, Wisconsin), such as the Rivetti-LevinsonTM Shunt, for example.
  • the shunt may also be a shunt apparatus such as is disclosed in co-pending and commonly assigned patent application for "Intraluminal Shunt and Methods of Use," Serial No. 09/034,849, invented by French et al., the entire contents of which are expressly incorporated by reference herein.
  • the shunt 132 generally includes a primary tubular member 134 which is adapted for insertion into the vessel and which is conformably and slidably received about the extension tube 112.
  • the extension tube 112 acts as a support body to support the shunt
  • the primary tubular member 134 defines at least one perfusion lumen defining a perfusion path through the primary tubular member 134 and provides a blood perfusion path within the vessel.
  • the shunt 132 also includes at least one side arm 136 fluidly coupled to the primary tubular member 134.
  • the side arm 136 defines an inner lumen therein in fluid communication with the primary tubular member lumen, thus defining a fluid or drug delivery path into the vessel.
  • a conventional luer adapter 137 is connected at the proximal end of side arm 136 and can be used to connect the shunt 132 to other fluid carrying members.
  • the shunt 132 may also include a peel-away grasping flange 138 which can be used by the surgeon to guide the shunt 132 along extension tube
  • shunt 132 may be slidably coupled to tube 112 in a press-fit or interference-fit relationship so that it will retain its position relative to tube 112 during the insertion and placement in the vessel.
  • the grasping flange 138 includes one or more suture holes 139 through which a suture(s) can be passed to secure the shunt 132 proximate the vessel prior to its insertion.
  • the shunt also preferably includes two spaced-apart occlusion members in the form of bulbous projections 133 which extend about the primary tubular member 134 close to the opposite ends of the primary tubular member 134, respectively.
  • Occlusion members 133 are constructed of any suitable biocompatible material, preferably silicone. Occlusion members 133 help to secure the primary tubular member in the vessel during use of the shunt 132 and to seal the vessel to force blood through the shunt. The occlusion members 133 also help to dilate and hold open the coronary arteriotomy while also reducing or preventing bleeding into the surgical field.
  • device 110 can be used to facilitate an anastomosis procedure in which a bypass graft vessel, such as an arterial graft (e.g., the left or right internal mammary artery) or a venous graft (such as a saphenous vein), is connected to a coronary artery.
  • a bypass graft vessel such as an arterial graft (e.g., the left or right internal mammary artery) or a venous graft (such as a saphenous vein)
  • the device 110 can be used to facilitate other procedures as well in which a fluid or drug, such as a therapeutic or diagnostic agent, needs to be administered directly, locally to a vessel.
  • Device 110 is particularly well-suited to facilitate a single or multiple bypass graft procedure in which the right (or left) coronary artery (which is typically the site of drug administration in the preferred use of the device to facilitate a TransarrestTM procedure) has a stenosed region which needs to be bypassed.
  • the patient is prepared for open-chest surgery using the TransarrestTM platform in a similar manner as described above in connection with the previous embodiment of Figures 1-4.
  • the surgeon prepares the target location on the right coronary artery 75 by removing fat tissue and the like to expose the external surface of the vessel.
  • the surgeon stabilizes the heart on opposite sides of the vessel by applying proximal fmger pressure to the heart surface on either side of the vessel. Mechanical stabilizers may also be used to stabilize a portion of the vessel.
  • the surgeon then makes a small puncture in the vessel with needle assembly 124 until a small backflash of blood is visualized through the needle hub.
  • the fluid delivery portion 115 of catheter 11 1 is then advanced a short distance into the artery 75 as shown in Figure 7.
  • the surgeon then removes needle assembly 124 in a generally straight continuous motion to prevent kinking of the extension tube 112 as illustrated by the arrow in Figure 7.
  • Flow control plug 125 may then be secured to side arm 120 to prevent the flow of blood or other body fluids through the inlet opening to arm 120 as shown in Figure 8.
  • surgeon may also advance shunt 132 distally towards the vessel as illustrated by the distally-pointing arrow in Figure 8 until the shunt 132 is located proximate the vessel.
  • the surgeon may then thread one or more sutures through the suture hole(s) 139 provided in grasping flange 138 to secure the shunt 132 to a surface of the heart proximate the vessel to prevent substantial movement of the shunt relative to the vessel and extension tube 112 as illustrated schematically in Figure 8 A.
  • the extension tube 1 12 is grasped by the surgeon or surgeon's assistant and secured to a retractor or similar fixed support structure.
  • the extension tube may be secured to the chest cavity using a clip (not shown) attached to the hub 118 or by using a similar fixation mechanism attached to the hub.
  • the extension tube 112 can then be connected to a conventional fluid carrying member, such as an IV pump or syringe, using adapter hub 118 for delivery of a fluid or drug to the vessel.
  • a liquid containing a cardioplegia solution is directed through the tube 112 and into the artery 75 which is capable of reversibly inducing ventricular asystole in the heart while maintaining the ability of the heart to be electrically paced, as described previously.
  • the surgeon When the surgeon is ready to graft to the right coronary artery 75, the surgeon enlarges the small needle puncture site in the vessel made by needle assembly 124 with a standard scalpel 150 or other appropriate surgical cutting instrument as shown in Figure 9.
  • This cutting procedure may be performed while the heart is temporarily arrested under the action of the pharmaceutical agents described above and while the pacer is temporarily deactivated. The surgeon may then cut through the sutures which connect the shunt 132 to the surface of the heart and peel away the grasping flange 138 from the shunt 132, which allows the shunt 132 to be slidably moved axially relative to extension tube 1 12.
  • This peel- away action is achieved by tearing a thin skin or bridge connecting the flange to the shunt using one's hand, a scalpel, scissors, or other appropriate cutting instrument.
  • the shunt 132 can be moved along extension tube 112 distally towards the vessel by grasping side arm 136 with forceps or a similar device until the shunt is inserted into the artery. This portion of the procedure is preferably performed on a temporarily arrested heart to facilitate insertion of the shunt 132 into the vessel. With the shunt partially within the vessel, the surgeon then removes intravascular catheter 111 from the vessel as illustrated by the proximally-pointing arrow in Figure 9. The shunt 132 is then fully inserted into the vessel ( Figure 10).
  • the luer adapter 137 can be used to connect the shunt 132 to IV tubing and the like to continue the administration of the pharmaceutical composition(s) described above (e.g., to deliver into the vessel the one or more periodic bolus infusions of carbachol or the continuous infusion of carbachol) to maintain ventricular asystole of the heart.
  • the surgeon can then graft to the right coronary artery 75 while the heart is intermittently arrested (e.g., by selectively turning the pacer off and on) and while the shunt 132 is in place within the vessel.
  • the shunt 132 provides distal perfusion to the vessel and prevents ischemia, while also maintaining a substantially blood-free zone in the surgical field.
  • the surgeon or surgeon's assistant With the shunt 132 in place within the vessel, the surgeon or surgeon's assistant then loosely places about five suture loops of 5/0 polypropylene, for example, around the "heel" of the graft vessel (e.g., an internal mammary artery or a saphenous vein) and passes the sutures through the wall of the coronary artery.
  • the suture loops are pulled up to approximate the graft vessel to the coronary artery while leaving a sufficient space between the vessels to allow for removal of the shunt 132 from the coronary artery 75.
  • Doty R.B.
  • FIGS. 1 1-15 two additional alternative embodiments of a fluid delivery device constructed in accordance with the principles of the present invention are disclosed.
  • Both of the proceeding devices are provided with a fluid delivery member which is movably coupled to a support member, the support member being adapted to be secured proximate the vessel to assist in guiding the fluid delivery member into the vessel.
  • the devices are generally more complex than the previously disclosed embodiments of the invention, the following devices have the advantage of providing the surgeon with greater control, stability, and precision during the insertion and placement of the fluid delivery member into the vessel.
  • Fluid delivery device 210 generally includes an elongate tubular body, or extension tube, 212 having a proximal end portion 214, a distal end portion 216 having a distal opening 217 therein (see Figures 12 and 12A), and an axial lumen 218 (see Figure
  • the distal end of the tubular body 212 is slightly rounded (see Figure 12 A) and soft to minimize trauma to the vessel when the distal end is retained adjacent thereto as will be explained below.
  • Elongate tubular body 212 is integrally connected to a handle 220 at the proximal end of the tubular body 212.
  • Handle 220 is configured to be grasped by the surgeon to allow the surgeon to grip and support the device 210 during placement of the fluid delivery member into the vessel as will be explained further below.
  • Tubular body 212 is preferably a relatively rigid, plastic or metal tube having an outer diameter of between about 2 and 10 mm, and preferably between about 3 to 5 mm, so as to engage about the surface of a coronary vessel.
  • Tubular body 212 is shown in the drawings as having a generally circular cross-sectional configuration. However, it is within the scope of the invention for tubular body 212 to have other configurations, including, but not limited to, square, rectangular, oval or channel or any other useful cross-sectional configuration.
  • Tubular body 212 may also be curved or angled.
  • a vacuum control assembly 240 is operably coupled to handle 220 and tubular body 212 for creating a suction holding force at the distal end opening 217 of the tubular body 212.
  • the handle 220 is provided with an internal vacuum lumen 242 which connects the vacuum control device 244 to the tubular body lumen 218.
  • the vacuum control device 244 is preferably a vacuum "on/off mechanism, but may be any other equivalent mechanism that operates to selectively open and close the vacuum pathway provided by vacuum lumen 242.
  • MINIMATIC® three way poppet valve Model No. MAV-3, Cincinnati, Ohio, is a preferred vacuum control device for use in the vacuum control assembly, and threadably engages with the handle 220.
  • a vacuum hose 246 connects the vacuum control device 244 with an external vacuum source (not shown). Vacuum applied from the vacuum source is then effectively applied at the distal end opening 217 of tubular body 212 via the pathway provided by components 246, 244, 242 and 218.
  • the application of vacuum to the distal end opening 217 of the lumen 218 is initiated by pressing "on/off button 241 of the vacuum control device 244, and discontinued by releasing the button.
  • the vacuum "on/off button is operable to connect the vacuum conduit 242 to the vacuum source to create a suction force within tubular body lumen 218 when the button 241 is actuated by the practitioner, as will be explained in greater detail below.
  • the suction force created within lumen 218 by actuation of vacuum "on/off button 241 is sufficient to retain a surface of the vessel, such as the right coronary artery, adjacent (e.g., in contact with or near) the distal, open end opening 217 of tubular body 212 to facilitate insertion of fluid delivery member 230.
  • the fluid delivery device 210 also preferably includes at least one atraumatic tissue contact member 260 which can be used to help align the device with the longitudinal aspect of the vessel and/or stabilize a heart surface proximate the vessel (in lieu of suction force provided by vacuum control assembly 244).
  • the tissue contact member comprises a left foot 262 and a right foot 264 which are placed to straddle the vessel where fluid administration is to occur.
  • the left and right feet 262, 264 extend laterally from the distal end portion 216 of the tubular body and are arranged in a parallel orientation with one another.
  • the lower surfaces of feet 262, 264 may be substantially planar or slightly curved to conform to the shape of the heart and are adapted to make contact with a tissue surface of the heart about the vessel when in use with the vacuum to help align the device (e.g., the distal end of tubular body 212) with the vessel.
  • Figure 12A is a bottom, perspective view of the distal portion of the device 210 giving another view of the feet 262,
  • the feet can be made from a biocompatible, non-toxic metal material such as stainless steel or a plastic material such as polycarbonate. Although the feet are shown fixed at the distal end of the tubular body 212, the feet 262, 264 can also be arranged to swivel, or rotate, about the longitudinal axis of the tubular body 212 to add more flexibility to the distal end of the device to accommodate large variations in the relative position of the vessel relative to the surface of the heart. This may be important due to the large variances in vessel anatomy across a diverse patient population. Such rotation could be accomplished, for example, by coupling the feet to a locking ball joint (not shown) provided near the distal end portion of the tubular body 212 which is adapted for rotational movement.
  • a locking ball joint not shown
  • the locking ball joint allows the position of the tubular body 212 to be varied in any direction relative to feet 262, 264.
  • One example of such a locking ball joint configuration is fully disclosed in U.S. Patent No. 5,894,843, the entire contents of which are incorporated by reference herein.
  • the device 210 further includes a fluid delivery member 230 which is configured to ride within a groove, or channel, 225 extending along a portion of the elongate tubular body 212.
  • the fluid delivery member includes a main body portion 232 which is shaped to be conformably received within channel 225 and to be slidably moveable relative to channel 225.
  • the main body portion is removably secured to channel 225 in a first position of the fluid delivery member 230 (e.g., when the fluid delivery member 230 is located external to the vessel) by a press-fit or interference-fit relationship.
  • the fluid delivery member 230 generally includes a needle insertion assembly 234 which includes a proximal needle hub 235 which is connected to a flexible needle wire 236, such as a Nitinol needle wire, for example, to allow the needle to assume a pre-treated curved configuration conforming to the general curvature of the body portion 232.
  • a shape can be easily generated by shaping the shape-memory Nitinol wire into the desired configuration and heat-treating the wire in that configuration, e.g., heating the wire beyond a specific "memory temperature" to give the wire a memory capability for this shape.
  • the distal end 238 of the wire 236 is beveled to create a sharp vessel penetration tip which can be used to puncture the vessel to insert the cannula portion 233 of fluid delivery member 230 into the vessel.
  • the configuration of cannula portion 233 is generally similar to the configuration of the cannula portion 20 of device 10.
  • the fluid delivery member 230 also includes a pair of suture wings 239 extending laterally from the body portion 232 which each include one or more suture holes 231 through which a suture can be tied to secure the fluid delivery member 230 proximate the vessel prior to fluid or drug administration therethrough.
  • the patient is prepared for surgery in a similar fashion as described above in relation to the previous embodiments.
  • the surgeon prepares the target location on the right coronary artery by removing fat tissue and the like to expose the external surface of the vessel.
  • the surgeon places the device 210 proximate the vessel such that the alignment feet 262, 264 straddle the vessel to provide a visual reference location on the heart to aid in the precise positioning of the fluid delivery member 230 into the vessel.
  • the surgeon then actuates the suction force by pushing on button 241 to enhance the securement of the device proximate to the surface of the vessel.
  • the operating surgeon or surgeon's assistant can then slide fluid delivery member 230 axially relative to tubular body 212 distally towards the vessel until needle 238 makes a small puncture, or opening, in the vessel.
  • the cannula portion 233 of the fluid delivery member 230 is then advanced a short distance into the artery, and then the elongate tubular body 212 separated therefrom and removed from the surgical field. With the cannula portion 233 partially in the vessel, the surgeon then removes needle insertion assembly 234 proximally away from the vessel.
  • FIG. 14-15 an alternative embodiment of the invention is shown and generally indicated with the reference numeral 310.
  • Device 310 is similar to the previous embodiment in that it also includes a support or stabilizing member operatively coupled to the fluid delivery device which securely retains a fluid delivery member at a desired location proximate the vessel to allow for easy insertion of the device into the vessel.
  • device 310 also includes actuators to allow the practitioner to accurately control the incident angle of insertion and the penetration depth of the fluid delivery member into the vessel. This may be important to provide the practitioner with greater control over the fluid delivery member to prevent the needle or the fluid delivery portion of the fluid delivery member from inadvertently piercing through the wall of the target vessel opposite the insertion site.
  • the device 310 generally includes a fluid delivery member 320 which is operatively coupled to a support member 330.
  • Fluid delivery member 320 can have a similar configuration to the fluid delivery member 230 described above.
  • fluid delivery member 320 can be, for example, a 24 gauge Insyte-W® IV catheter available from Becton-Dickinson (Sandy, Utah) or other similar commercially available IV infusion catheter.
  • fluid delivery member 320 includes a cannula portion 322 (which can be similar to any of the cannula portions described previously), a needle insertion assembly (not shown), a main body portion 321, laterally extending suture wings 326 (having one or more suture holes 327 therein), and hub portion 328.
  • Support member 330 generally comprises a generally rectangular housing 332 and a generally rigid anchoring base portion 334 rotatably coupled to the housing 332.
  • the base portion 334 is configured to secure the device proximate to the vessel insertion site.
  • Base portion 334 is made from a suitable plastic material such as polyurethane and has a generally flat bottom surface to prevent abrasion to the vessel and/or tissue surface proximate the vessel when it is secured thereto.
  • the base portion 334 could also have a smooth, generally convex configuration to better conform the base portion to the contoured surface of the heart.
  • the base portion could also include one or more laterally extending flanges (not shown) which can include one or more suture holes therein to allow the base portion to be stably sutured to a tissue surface of the heart proximate the intended target vessel.
  • other means to secure the base portion 334 proximate the vessel can be employed as well, such as, for example, applying an adhesive to the lower surface of the base portion, such as cyanoacrylate, e.g., Loctite®, manufactured by Loctite Corporation (Hartford, CT) or applying a self-adhesive backing to the base portion to secure it to the heart, such as described previously.
  • the adhesive should preferably be compatible with biological tissue surfaces and the like and should be capable of easily being flaked off of the tissue surface following removal of the device therefrom.
  • the base portion 334 could also be configured to include a suction capability to enhance securement of the base portion proximate the vessel.
  • the base portion 334 could include one or more suction holes (not shown) through its bottom surface which fluidly communicate with a suction channel through a portion of the base portion. The suction channel in turn would communicate with a vacuum source which would be operatively coupled to the base portion 334 to effect a suction force at the bottom surface.
  • the base portion 334 is rotatably coupled to housing 332 via a rotatable knob 335.
  • Rotatable knob 335 in turn is fixedly attached to a rigid bar member (not shown for clarity) which is rotatably coupled to base portion 334 (base portion 334 acts as a bearing member to allow the bar member and knob 335 to rotate with respect to the base portion) and which is rigidly attached to a lower portion of housing 332 (e.g., by a press-fit or interference fit relationship). Accordingly, rotation of housing 332 relative to base portion 334 upon manipulation of knob 335 changes the incident angle of insertion of the cannula portion 322 of the fluid delivery member 320.
  • the housing 332 and/or base portion 334 may include indicia (not shown) which indicate the particular incident angle of the fluid delivery member 320 relative to the vessel insertion site based on rotation of knob 335.
  • the housing 332 can be rotated to any number of positions to suit a variety of particular applications.
  • the housing also preferably includes an actuator 340 which can be manipulated by the practitioner to accurately control the depth at which the needle insertion assembly portion of fluid delivery member 320 is inserted into the vessel.
  • actuator 340 includes a threaded rod 342 which extends lengthwise along the vertical dimension of housing 332 through a cut-out portion 343 of the housing.
  • An annular actuation ring 344 is threadably coupled to rod 342.
  • Actuator 340 also includes a bracket 346 which rigidly secures the fluid delivery member 320 to the actuation ring 344.
  • the main body portion 321 of the fluid delivery member 320 is configured to mate with the bracket 346 in a snap-fit or slight interference-fit relationship to rigidly secure the fluid delivery member 320 to the bracket, and also allow the fluid delivery member 320 to be easily separated from the bracket following insertion of the cannula portion of the fluid delivery member into the vessel.
  • the bracket 346 may be rigidly secured to the actuation ring 344 by any suitable means such as by welding or brazing.
  • the thread form relationship between actuation ring 344 and rod 342 means that rotation of actuation ring 344 will translate into axial, linear movement of fluid delivery member 320.
  • housing 332 are formed in either side of housing 332 to permit passage of the bracket 346 vertically through the housing 332. In this way, linear movement of fluid delivery member 320 into the vessel can be accurately controlled to prevent piercing or trauma to the backside of the vessel during device insertion.
  • the fluid delivery member 320 can be separated from bracket 346 and the support member 330 discarded. The fluid delivery member may then be sutured proximate the vessel using suture wings 326.
  • the housing 332 can include indicia 350 on the sides of the housing to indicate the particular vertical orientation of the fluid delivery member 320 relative to the vessel insertion site.
  • the devices 210 and 310 described above are assembled such that the fluid delivery member is removably coupled to the support member, it is contemplated that the fluid delivery member also could be de-coupled from the support member and provided or packaged as a separate part from the support member. In this way, the support member could be first secured to a tissue surface near to or on the vessel proximate the device insertion site, and then the fluid delivery member could be coupled to the support member.
  • the device 10 of the first embodiment of the invention can also include a shunt coupled to the cannula portion 20 of the device similar to the configuration of the device 110.
  • the shunt may be secured to the cannula portion 20 by removably securing a portion of the shunt to connector 30.
  • a portion of the connector 30 could be configured to be broken away from or separated from the remaining portion of the connector 30 to allow the shunt to be separated therefrom and inserted into the vessel.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

L'invention concerne des dispositifs de distribution de fluide permettant de diffuser directement un fluide ou un médicament dans un vaisseau, tel qu'un vaisseau coronaire sur un coeur battant. Un de ces dispositifs comporte généralement une canule allongée pourvue d'une extrémité proximale, d'une extrémité distale et d'au moins une lumière allant de l'extrémité proximale à l'extrémité distale de la canule. Un connecteur couplé à la canule à proximité de l'extrémité proximale définit au moins une première lumière et une seconde lumière. Au moins l'une de ces deux lumières s'étend coaxialement à la lumière de la canule, avec laquelle elle est en communication fluidique. Une aiguille d'insertion, pourvue d'une extrémité distale effilée, est disposée de façon mobile dans le sens de la longueur dans la première lumière et dans la lumière de la canule. Un corps tubulaire allongé et souple est couplé de façon fonctionnelle à la seconde lumière du connecteur, avec laquelle elle est en communication fluidique.
PCT/US2000/040118 1999-06-03 2000-06-05 Dispositif et procede de distribution de fluide a injection directe WO2000074750A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU64023/00A AU6402300A (en) 1999-06-03 2000-06-05 Direct injection fluid delivery device and method

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32475699A 1999-06-03 1999-06-03
US09/324,75619990603 1999-06-03

Publications (1)

Publication Number Publication Date
WO2000074750A2 true WO2000074750A2 (fr) 2000-12-14

Family

ID=23264969

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/040118 WO2000074750A2 (fr) 1999-06-03 2000-06-05 Dispositif et procede de distribution de fluide a injection directe

Country Status (2)

Country Link
AU (1) AU6402300A (fr)
WO (1) WO2000074750A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015104089A1 (fr) * 2014-01-10 2015-07-16 Spielmann Alain Nécessaire de traitement chirurgical et procédé de préparation associé
JP2017528227A (ja) * 2014-09-11 2017-09-28 ピーシビダ ユーエス，インコーポレイテッド 注入機器

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015104089A1 (fr) * 2014-01-10 2015-07-16 Spielmann Alain Nécessaire de traitement chirurgical et procédé de préparation associé
JP2017528227A (ja) * 2014-09-11 2017-09-28 ピーシビダ ユーエス，インコーポレイテッド 注入機器
US10363163B2 (en) 2014-09-11 2019-07-30 EyePoint Pharmaceuticals, Inc. Injector apparatus

Also Published As

Publication number Publication date
AU6402300A (en) 2000-12-28

Similar Documents

Publication Publication Date Title
US5875782A (en) Methods and devices for minimally invasive coronary artery revascularization on a beating heart without cardiopulmonary bypass
US6095997A (en) Intraluminal shunt and methods of use
US6711436B1 (en) Compositions, apparatus and methods for facilitating surgical procedures
US6325067B1 (en) Methods and systems for performing thoracoscopic coronary bypass and other procedures
US6027476A (en) Methods and systems for performing thoracoscopic coronary bypass and other procedures
JP3322404B2 (ja) インビボの血管バイパスを形成するためのカテーテル機器及びカテーテル機器に用いるカフス
US5807384A (en) Transmyocardial revascularization (TMR) enhanced treatment for coronary artery disease
US5584803A (en) System for cardiac procedures
US7077801B2 (en) Methods and devices for improving cardiac output
US5558644A (en) Retrograde delivery catheter and method for inducing cardioplegic arrest
US6322548B1 (en) Delivery catheter system for heart chamber
US6283983B1 (en) Percutaneous in-situ coronary bypass method and apparatus
EP0841963B1 (fr) Systeme de catheters de cardioplegie
AU2021232831B2 (en) Fenestration devices, systems, and methods
JPH11239619A (ja) カテーテル
Reichenspurner et al. Minimally invasive mitral valve surgery using three-dimensional video and robotic assistance
WO2000029056A2 (fr) Procedes et appareil de distribution de fluide
WO2000074750A2 (fr) Dispositif et procede de distribution de fluide a injection directe
US20020100482A1 (en) Methods and systems for performing thoracoscopic coronary bypass and other procedures
WO2001017582A2 (fr) Systeme d'administration de medicament par shunt a bifurcation et procede d'utilisation
Gerosa et al. Cannulations for cardiopulmonary bypass
Coady et al. Type A Aortic Dissections

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642